BioAlliance Pharma Presents Results on Its New Biotherapy Plasmid AMEP(TM) for Metastatic Melanoma at the American Association for Cancer Research 100Th Annual Meeting in Denver, April 18 to 22, 2009

PARIS--(BUSINESS WIRE)--Regulatory News: BioAlliance Pharma SA (Paris:BIO), a specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV, has presented results on its new biotherapy, plasmid AMEP™, for metastatic melanoma treatment at the at the American Association for Cancer Research (AACR) 100th Annual Meeting, in Denver, April 18 to 22, 2009.